Urinary Bladder Neoplasms: all 1,649 studies

Page 10 of 17. Open to participants first (427), then studies with results posted, then the rest; newest registration first within each.

• Establishment and Validation of an Early Diagnostic Model for Bladder Cancer Based on Serum and Urine MetabolomicsStatus unknownNCT04966962
• Lateral Prostate Capsule Sparing Versus Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the MaleStatus unknownNCT04966949Not applicable
• Effect of Urinary Indwelling Time on Early Continence After Robot-assisted Radical Cystectomy With Orthotopic Ileal Neobladder.Status unknownNCT04966130
• Sexual Quality of Patients After Bladder Cancer CystectomyCompletedNCT04964895
• Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and ImmunotherapyActive, not recruitingNCT04963153Phase 1
• Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3
• Application and Clinical Effectiveness of Pelvic Reconstruction in Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder in the MaleStatus unknownNCT04958343
• Lateral Prostate Capsule Sparing Versus Non Nerve Sparing Robot-assisted Radical Cystectomy-orthotopic Ileal Neobladder for Bladder Cancer in the MaleStatus unknownNCT04958330
• ARID1A and/or KDM6A Mutation and CXCL13 ExpressionActive, not recruitingNCT04953104Phase 2
• Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaActive, not recruitingNCT04940299Phase 2
• Fast Track Protocol After Radical Cystectomy and Urinary Diversion: A Randomised Controlled Trial.Status unknownNCT04939194Phase 3
• Safety and Efficacy Study of Tislelizumab in Combination With BCG in HR-NMIBC Patients (TACBIN-01)Status unknownNCT04922047Phase 1/2
• A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder CancerActive, not recruitingNCT04917809Phase 2
• Chemotherapy Combined With Tislelizumab as Bladder Sparing Option for Patients With Muscle Invasive Bladder CancerStatus unknownNCT04909775Phase 2
• The Effect of the COVID-19 Pandemic on Primary Bladder Cancer PresentationsCompletedNCT04900259
• Study of ESG401 in Adults With Solid TumorsCompletedNCT04892342Phase 1/2
• Efficacy and Safety of Obturator Nerve Block During Transurethral Resection on Non-muscle Invasive Intermediate and High Risk Lateral Wall Bladder TumoursCompletedNCT04885309Not applicable
• Preoperative Bintrafusp Alfa in Operable Urothelial Carcinoma of the BladderStatus unknownNCT04878250Phase 2
• Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma PatientsActive, not recruitingNCT04863885Phase 1/2
• Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder CancerStatus unknownNCT04859751Phase 3
• Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial CarcinomaActive, not recruitingNCT04848519Phase 2
• Bipolar Versus Mono-polar Needlescopic En Bloc TUR-BTStatus unknownNCT04839029Not applicable
• Trial of Open Versus Laparoscopic Radical Cystectomy at a Laparoscopic Naive CenterCompletedNCT04838873Not applicable
• DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study)CompletedNCT04825834
• Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBCCompletedNCT04819399Phase 1
• A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder CancerStatus unknownNCT04813107Phase 1/2
• Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder CarcinomaStatus unknownNCT04812145
• CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and BloodActive, not recruitingNCT04811846Not applicable
• Immunological Response of Bladder Cancer Patients Under BCGCompletedNCT04806178Phase 3
• Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG VaccineStatus unknownNCT04799847Phase 1/2
• Study of ONCOFID-P-B™ (PACLITAXEL-HYALURONIC ACID)CompletedNCT04798703Phase 1
• Study of IDE397 in Participants With Solid Tumors Harboring MTAP DeletionActive, not recruitingNCT04794699Phase 1
• En-Bloc Resection of Bladder TumorsStatus unknownNCT04784507Phase 2
• Urothelial Cancer Tumor Bio-markers and Physical-spectroscopic CharacteristicStatus unknownNCT04770974
• Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression RatesCompletedNCT04768894Not applicable
• Evaluation of the PhageTech Virus BioResistorStatus unknownNCT04756284
• Relationship Between Methods of Bladder Tumor Extraction and Local Recurrence RateStatus unknownNCT04750590Not applicable
• Adjuvant Radiotherapy Versus Observation After Radical Cystectomy in High Risk Urothelial Bladder CancerStatus unknownNCT04740866Not applicable
• Study of HX008 for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT04738630Phase 2
• Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely ResectableStatus unknownNCT04730232Phase 2
• Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder CarcinomaStatus unknownNCT04730219Phase 2
• Evaluation of PD-L1 Expression and Immune Infiltration in High-risk Non Muscle Invasive Bladder CancerCompletedNCT04726735
• Can We Predict of the Response of High Risk Non Muscle Invasive Bladder Cancer Patients to Intravesical Bacillus Calmette-Guerin? The Role of Immunological MarkersCompletedNCT04723121Not applicable
• Multimodal Spectroscopy to Detect Urothelial Cancer in UrineStatus unknownNCT04718948
• the Efficacy and Safety of LDP in Patients With Urinary and Male Genital TumorsCompletedNCT04718584Phase 2
• Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG TreatmentActive, not recruitingNCT04706598Phase 1/2
• Cryoablation With Pembrolizumab Or Avelumab In Urothelial CarcinomaCompletedNCT04701918Phase 2
• Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)Active, not recruitingNCT04700124Phase 3
• Gender-related Characteristics of Bladder Cancer TreatmentStatus unknownNCT04687254
• a Genome-based Platform to Predict Patients That Can Achieve Bladder Preservation in Muscle Invasive Bladder Cancer PatientsStatus unknownNCT04686149
• Bakircay University Cigli Training and Research HospitalCompletedNCT04683536
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder CancerStatus unknownNCT04664816Not applicable
• ONCOFID-P-B in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder.CompletedNCT04661826Phase 2
• A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the BladderActive, not recruitingNCT04658862Phase 3
• Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder CancerStatus unknownNCT04644835Not applicable
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• Comparison of Obturator Nerve Block With Ultrasound Guidance and Anatomical SignsStatus unknownNCT04638569Not applicable
• Pharmacological Enhancement for Nocturnal Incontinence in Orthotopic Bladder SubstituteCompletedNCT04635566Not applicable
• Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCActive, not recruitingNCT04630730Phase 2
• The Effect of Post-voiding Reisdual Urine on Non-muscle Invasive Bladder Cancer Recurrence and ProgressionCompletedNCT04617743
• Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBCCompletedNCT04610671Phase 1
• Ileal Conduit Versus Cutaneous Ureterostomy After Radical CystectomyStatus unknownNCT04610385
• The Role of mRNA-based Urine Test (Xpert Bladder Cancer Monitor) in Predicting the Need for Second Look Biopsy After Transurethral Resection of Non Muscle-invasive Bladder Tumor.CompletedNCT04603612Not applicable
• A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER TabletsCompletedNCT04601766Phase 1
• Addressing Barriers to Palliative Care Use in Bladder CancerCompletedNCT04598724
• Bladder Cancer and ExeRcise Training During IntraVesical ThErapyCompletedNCT04593862Phase 2
• Comparative Microbial Analysis of Cystitis in Non-muscle-invasive Bladder Cancer Patients Using Vikor Scientific Urine-ID Testing Menu (IDTM) and Standard Laboratory CultureWithdrawnNCT04583553
• INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid TumorsCompletedNCT04580485Phase 1
• Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial CancerActive, not recruitingNCT04579224Phase 3
• Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical CystectomyTerminatedNCT04579133Phase 2
• Holmium Versus Bipolar en Bloc Transurethral Resection of Urothelium Tumor of the Urinary BladderCompletedNCT04576286Phase 2
• Measuring Taste Perception During Chemotherapy for Muscle Invasive Bladder CancerActive, not recruitingNCT04567719
• Preventing Viral Pandemic Associated Risk of Cancer Death Using Less Invasive Diagnostic Tests- Liquid BiopsiesCompletedNCT04566614
• Chidamide With Immunotherapy for Patients With Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT04562311Phase 2
• Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesActive, not recruitingNCT04561362Phase 1/2
• Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Local Advanved Bladder CancerCompletedNCT04553939Phase 2
• Radiation and Durvalumab Immunotherapy As Neoadjuvant Treatment for MIBCStatus unknownNCT04543110Phase 2
• Dietary Fiber During Radiotherapy - a Placebo-controlled Randomized TrialCompletedNCT04534075Phase 3
• Multiparametric Magnetic Resonance Imaging (MRI) to Improve Bladder Cancer Staging and Treatment Decision-makingCompletedNCT04533672Not applicable
• Clinicoepidimiological Study and Clinical Outcome in Patients With Urinary Bladder CancerStatus unknownNCT04525781
• Preoperative Subclinical DVT Screening in Locally Advanced Bladder Cancer Patients Candidate for Radical Cystectomy.Status unknownNCT04502498
• Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesCompletedNCT04501913
• Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG TherapyCompletedNCT04498702Phase 2
• Propranolol Adjuvant Treatment of Bladder CancerStatus unknownNCT04493489Phase 2
• Safety and Efficacy of APL-1202 in Combination With Epirubicin Hydrochloride Versus Epirubicin Hydrochloride Alone in Intermediate and High-risk Chemo-refractory Non-muscle Invasive Bladder Cancer (NMIBC) PatientsStatus unknownNCT04490993Phase 3
• Prospective Study to Evaluate the Blood Kinetics of Immune Cells and Immunosuppressive Cytokines After Exposure to an Immunity Checkpoint Inhibitor (ICI): Study of the Impact of ChemotherapyCompletedNCT04487457
• TTX-080 HLA-G Antagonist in Subjects With Advanced CancersActive, not recruitingNCT04485013Phase 1
• Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersWithdrawnNCT04464967Phase 1/2
• Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various CancersActive, not recruitingNCT04459273Phase 1
• AN0025 and Pembrolizumab Combination in Advanced Solid TumorsActive, not recruitingNCT04432857Phase 1
• Assessement of the Concordance of Genomic Alterations Between Urine and Tissue in High-Risk NMIBC PatientsTerminatedNCT04412070
• Assessment of Urinary Diversions Outcomes Post Radical Cystectomy in Asyut University Urology HospitalStatus unknownNCT04406168
• Quadratus Lumborum Block vs Transversus Abdominis Plane Block in Bladder Cancer SurgeriesStatus unknownNCT04402411Not applicable
• Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCompletedNCT04387461Phase 2
• Clinical Study of Gastric Cancer, Colorectal Cancer and Bladder Cancer Based on Liquid BiopsyStatus unknownNCT04385316
• The Impact of Preoperative Urostomy Education on Patients and FamiliesCompletedNCT04334226
• Complete Local Response to Neoadjuvant Chemotherapy in Patients With Muscle Invasive Bladder Cancer Evaluated by 15O-H2O PET/MRCompletedNCT04321707Not applicable
• Oncological Outcomes of Different Patterns of Tumor Recurrence at First Evaluation After Bacillus Calmette-Guérin Induction Therapy for Intermediate and High Risk Non Muscle Invasive Bladder CancerCompletedNCT04319263Not applicable
• Role of Novel Urinary Genomic and Metablomic Markers in Diagnosis of Bladder Cancer in Patients With HematuriaCompletedNCT04317261Not applicable

← Urinary Bladder Neoplasms overview